Figure 1
From: The role of PD-L1 in the radiation response and clinical outcome for bladder cancer
PD-L1 levels in bladder cancer correlated with clinical outcome.
(a) Representative images of IHC staining with an anti-PD-L1 antibody of bladder cancer and adjacent non-malignant epithelium from TMA blocks (NT, adjacent non-malignant epithelium; CA, bladder cancer tissue). * (+) indicates positive staining in cancer > adjacent NT. (b) IHC staining with an anti-PD-L1 antibody of human bladder cancer specimens. Images of representative slides are shown at magnifications of ×100 (upper row) and ×200 (lower row). (c) Survival differences according to the staining of PD-L1 in overall survival with intact bladder; and disease-free survival (d) of bladder cancer patients treated with definite CCRT. The PD-L1-positive group exhibited reduced survival than the PD-L1-negative group.
